Drug Profile
T 250 - Trimeris
Latest Information Update: 29 Mar 2001
Price :
$50
*
At a glance
- Originator Trimeris
- Class Antiplatelets; Antivirals; Vascular disorder therapies
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parainfluenza virus infections
Most Recent Events
- 29 Mar 2001 Discontinued-Preclinical for Parainfluenza virus infections in USA (Unknown route)
- 02 Sep 1998 No-Development-Reported for Parainfluenza virus infections in USA (Unknown route)
- 12 Jun 1995 Preclinical development for Parainfluenza virus infections in USA (Unknown route)